Prognostic value of quantitative immune alterations in melanoma patients (original) (raw)

Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma

Giuseppe Palmieri

Frontiers in Oncology

View PDFchevron_right

Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients

Cristina Fortes

Journal of Cancer Research and Clinical Oncology, 2021

View PDFchevron_right

Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma

Mary Brady

Annals of Surgical Oncology, 2013

View PDFchevron_right

Aspects of cancer immunotherapy

Bruce Loveland

Immunology and Cell Biology, 2003

View PDFchevron_right

Immune dysregulation in cancer patients developing immune-related adverse events

Shaheen Banu Khan

British Journal of Cancer, 2018

View PDFchevron_right

Melanoma survival in the United States, 1992 to 2005

Lori Pollack

Journal of the American Academy of Dermatology, 2011

View PDFchevron_right

Influence of Sentinel Lymph Node Tumor Burden on Survival in Melanoma

Isabele Small

Annals of Surgical Oncology, 2010

View PDFchevron_right

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008

Wolfram Samlowski, Sancy Leachman

Pigment Cell & Melanoma Research, 2009

View PDFchevron_right

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Genny Del Zotto

Journal of Translational Medicine, 2018

View PDFchevron_right

The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma

Abdallah Badou

Frontiers in Immunology, 2023

View PDFchevron_right

“Bak (and Bax) to the Future” — of Primary Melanoma Prognosis?

harald gollnick

Journal of Investigative Dermatology, 2006

View PDFchevron_right

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Markus Frank

2023

View PDFchevron_right

Tumor screening and biology in malignant melanomas

Salvador J Diaz-Cano

2000

View PDFchevron_right

Supplementary Table 3 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Markus Frank

2023

View PDFchevron_right

Immunologic escape and angiogenesis in human malignant melanoma

Pedro Redondo

Journal of the American Academy of Dermatology, 2003

View PDFchevron_right

Cancer Immunotherapy: A breakthrough in patient care

Abdallah Badou

Health Sciences, 2022

View PDFchevron_right

Immunotherapy/Biological Therapies

iwan sumantri

Neuro-Oncology, 2013

View PDFchevron_right

Diagnostic spectrum of nodular melanoma

Ignazio Stanganelli

Clinical dermatology, 2016

View PDFchevron_right

Immunohistological correlation in different stages of squamous cell carcinoma

Claudiu Margaritescu

Romanian Journal of Morphology and Embryology, 2008

View PDFchevron_right

Paucity of Tumor-infiltrating Lymphocytes Is an Unfavorable Prognosticator and Predicts Lymph Node Metastases in Cutaneous Melanoma Patients

Rafał Matkowski

Anticancer Research, 2015

View PDFchevron_right

Immune system: a double-edged sword in cancer

Lakshmi Narendra

Inflammation Research, 2013

View PDFchevron_right

Insight into the management of patients with melanoma in times of the COVID-19 pandemic: A single-center experience

ivana mijatov

Vojnosanitetski pregled, 2024

View PDFchevron_right

Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies

Charles E. Terry

Cancer Immunology Research, 2015

View PDFchevron_right

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

Ena Wang

Journal of Translational Medicine, 2013

View PDFchevron_right

Immune-related dermatologic toxicities: to make a long story short

Dimitra Lambropoulou

Cutaneous and Ocular Toxicology, 2019

View PDFchevron_right